Evidence map›Paper›PMID 41213678›Full record

ArticleBMJ open2025

Examining differences in clinical and demographic characteristics of patients with post-traumatic stress disorder across adult treatment subgroups based on the NeuroBlu database: a non-interventional, retrospective cohort study.

Staci Abramsky, Suzanne St Rose, Yi Wen Heng, L Alexander Vance, Ling Zhang, Kelly My Chan, Joshua G Wong, Sherwin Kuah, Li Tong Low, Irina Adamczyk

Abstract read
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Staci AbramskyBoehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA staci.abramsky_risman@boehringer-ingelheim.com.ORCID http://orcid.org/0009-0004-1872-4274
Suzanne St RoseBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Yi Wen HengHolmusk Technologies, Inc, Singapore & New York, NY, USA.
L Alexander VanceHolmusk Technologies, Inc, Singapore & New York, NY, USA.
Ling ZhangBoehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.ORCID http://orcid.org/0000-0003-2472-9544
Kelly My ChanHolmusk Technologies, Inc, Singapore & New York, NY, USA.
Joshua G WongHolmusk Technologies, Inc, Singapore & New York, NY, USA.
Sherwin KuahBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Li Tong LowHolmusk Technologies, Inc, Singapore & New York, NY, USA.
Irina AdamczykBoehringer Ingelheim, Baden-Württemberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPost-traumatic stress disorder (PTSD) is a heterogeneous psychiatric disorder, with symptom variation between patients.

objectiveWe describe clinical and demographic characteristics of patients with PTSD based on real-world data.

methodsThis non-interventional, retrospective cohort study analysed de-identified electronic health records of patients from the Holmusk NeuroBlu database in the USA. Patients with ≥2 PTSD diagnoses captured in the database within 30 days between 2001 and 2020 were included. The index date was defined as the date of the first recorded PTSD diagnosis. In patients who were aged ≥18 years, demographic and clinical characteristics at baseline (index date ±14 days), in the 6 months prior to baseline and 12 months after baseline were described. Patients were stratified into four mutually exclusive subgroups according to treatment received: psychotherapy only, pharmacotherapy only, psychotherapy and pharmacotherapy, and untreated. Natural language processing models were used to derive PTSD symptoms from unstructured clinician-documented mental state examination data. Data were analysed descriptively.

findingsA total of 37,449 patients had ≥2 PTSD diagnoses within 30 days between 2001 and 2020; 32,875 patients received care at clinical sites with both inpatient/outpatient units; 25,507 patients received psychotherapy and/or pharmacotherapy as per further prespecified criteria, and 17,234 were ≥18 years old and included in this analysis. Most patients (84.9%) received psychotherapy, pharmacotherapy or both during the first year post-baseline. Mean age (SD) was 37.7 (12.4) years, 73.4% of patients were female and 59.6% were White. At baseline, 98% of patients had ≥1 psychiatric comorbidity; major depressive disorder (42.2%), substance use disorder (35%) and anxiety disorder (30.7%) were most frequently reported. Reported suicidal ideation/attempts were most frequent in the pharmacotherapy only group compared with other subgroups at baseline. The most frequently prescribed drug classes were antidepressants (51.8%), second-generation antipsychotics (29.9%) and anxiolytics (23.3%) at baseline. Trazodone, clonazepam, quetiapine and sertraline were the most frequently prescribed medications.

conclusionIn the overall study population, most patients were female, with a high prevalence of psychiatric comorbidities. Demographic and clinical characteristics observed in this study varied across treatment subgroups. These insights may support patient-specific treatment planning and inform health-economic decision models in PTSD.

Indexed as

PsychotherapyStress Disorders, Post-TraumaticAdultDatabases, FactualElectronic Health RecordsFemaleHumansMaleMiddle AgedRetrospective StudiesUnited StatesYoung AdultAdult psychiatryEPIDEMIOLOGYMENTAL HEALTHPSYCHIATRY

Identifiers

PMID41213678
PMCPMC12598942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.